CraigFTellerMDFAAD

Dermatology • Bellaire, TX

Acne & Rosacea, Cosmetic Dermatology, Dermatologic Surgery

Clinical Instructor, Dermatology, Baylor College of Medicine and McGovern UT school of Medicine

Join to view full profile

Dr. Teller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Teller's full profile

Already have an account?

Office
6565 West Loop South
Ste. 800
Bellaire, TX 77401
Phone+1 713-661-4383
Is this information wrong?

Summary

Dr. Craig Teller is a dermatologist in Bellaire, TX and is affiliated with multiple hospitals in the area, including Baylor St. Luke's Medical Center, Memorial Hermann Physician Network, and Memorial Hermann Southwest Hospital. He received his medical degree from McGovern Medical School at UTHealth and has been in practice 26 years. He specializes in acne & rosacea, cosmetic dermatology, and dermatologic surgery and is experienced in cosmetic dermatology, pediatric dermatology, complex medical dermatology, phlebology, and clincial trials. He has more than 10 publications and over 300 citings.

Education & Training

Baylor College of MedicineResidency, Dermatology, 1992 - 1995
University of Texas Health Science Center at HoustonInternship, Internal Medicine, 1991 - 1992
McGovern Medical School at UTHealthClass of 1991

Certifications & Licensure

TX State Medical License 1992 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Fellow (FASDS) American Society for Dermatologic Surgery
Fellow (FAAD) American Academy of Dermatology

Clinical Trials

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12
Active, not recruiting
Phase 3
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) Start of enrollment: 2020 Jun 15
Active, not recruiting
Phase 3
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema) Start of enrollment: 2015 Mar 31
Completed
Phase 2
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2013 May 01
Completed
Phase 2
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) Start of enrollment: 2013 Dec 31
Completed
Phase 2
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2018 Nov 12
Terminated
Phase 2
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2019 Jul 01
Active, not recruiting
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2019 May 13
Completed
Phase 3
Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2014 Nov 20
Completed
Phase 2
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa Start of enrollment: 2022 Apr 25
Completed
Phase 2
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) Start of enrollment: 2019 Feb 25
Completed
Phase 3
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) Start of enrollment: 2018 Jul 27
Active, not recruiting
Phase 3
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Start of enrollment: 2021 Jun 16
Completed
Phase 2
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Start of enrollment: 2018 Sep 24
Active, not recruiting
Phase 2, Phase 3
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Start of enrollment: 2012 Sep 01
Terminated
Phase 3
Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition Start of enrollment: 2018 Nov 12
Completed
Phase 3
Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency Start of enrollment: 2017 Dec 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

8 citations
ATX-101 (Deoxycholic Acid Injection) Leads to Clinically Meaningful Improvement in Submental Fat: Final Data From CONTOUR.
Kathleen L. Behr, Carmen M. Kavali, Girish Munavalli, Craig F Teller, Steve Yoelin, Laura Breshears, Sara Sangha> ;Dermatologic Surgery. 2020 May 1
12 citations
Aesthetic Treatment Positively Impacts Social Perception: Analysis of Subjects From the HARMONY Study.
Steven H. Dayan, Alexander Rivkin, Jonathan M. Sykes, Craig F Teller, Susan H Weinkle, Garrett T Shumate, Conor J. Gallagher> ;Aesthetic Surgery Journal. 2019 Nov 13
15 citations
Treatment of Atrophic Facial Acne Scars With Microneedling Followed by Polymethylmethacrylate-Collagen Gel Dermal Filler.
Brian S. Biesman, Joel L Cohen, Barry E. DiBernardo, Jason Emer, Roy G. Geronemus, Michael H. Gold, Alayne Lehman, Brian Pilcher, Gary D. Monheit, Todd E Schlesinger, ...> ;Dermatologic Surgery. 2019 Dec 1
37 citations
Impact of Comprehensive, Minimally Invasive, Multimodal Aesthetic Treatment on Satisfaction With Facial Appearance: The HARMONY Study.
Susan H Weinkle, W. Philip Werschler, Craig F Teller, Jonathan M. Sykes, Ava Shamban, Alexander Rivkin, Vic A. Narurkar, Michael S. Kaminer, Steven H. Dayan, Joel L. C...> ;Aesthetic Surgery Journal. 2018 Apr 6
25 citations
A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study.
Vic A. Narurkar, Joel L Cohen, Steven H. Dayan, Michael S. Kaminer, Alexander Rivkin, Ava Shamban, Jonathan M. Sykes, Craig F Teller, Susan H Weinkle, W. Philip Wersch...> ;Dermatologic Surgery. 2016 May 1
46 citations
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results
Alexa B. Kimball, Kenneth J. Rothman, Gregory Kricorian, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig F. Teller, Girish A. Aras, Neil A. Accortt, Michele Hoo...> ;Journal of the American Academy of Dermatology. 2015 Jan 1
11 citations
Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or pho...
Bruce Strober, Yves Poulin, Craig F. Teller, Y. Wang, David A. Williams, O.M. Goldblum> ;Journal of the European Academy of Dermatology and Venereology. 2014 Dec 1
28 citations
OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis
Alexa B. Kimball, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig F. Teller, Yifei Shi, Mellissa Yong, Kara Creamer, Michele Hooper, Girish A. Aras, Gregory Kri...> ;Journal of the American Academy of Dermatology. 2013 May 1
138 citations
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis
Bruce Strober, Craig F. Teller, Paul S. Yamauchi, Miller Jl, Michele Hooper, Yang Yc, F. Dann> ;The British Journal of Dermatology. 2008 Aug 1
21 citations
Primary hyperoxaluria in a 27-year-old woman.
Melissa A. Bogle, Craig F. Teller, Jaime A. Tschen, Carolyn A. Smith, Alun Wang> ;Journal of the American Academy of Dermatology. 2003 Oct 1
2 citations
Angiotropic large-cell lymphoma with striking blue plaques.
T.Minsue Chen, Mary K. Crow, Craig F. Teller> ;Journal of the American Academy of Dermatology. 2003 Apr 1
32 citations
Cutaneous manifestations of sports participation.
David B. Pharis, Craig F. Teller, John E. Wolf> ;Journal of the American Academy of Dermatology. 1997 Mar 1
Join now to see all